168 related articles for article (PubMed ID: 33299299)
1. Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach.
Abdelhameed AS; Attwa MW; Kadi AA
Drug Des Devel Ther; 2020; 14():5259-5273. PubMed ID: 33299299
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Fenebrutinib Metabolism and Bioactivation Using MS
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Molecules; 2023 May; 28(10):. PubMed ID: 37241965
[TBL] [Abstract][Full Text] [Related]
3. Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways.
Attwa MW; Kadi AA; Abdelhameed AS
J Sep Sci; 2020 Feb; 43(4):708-718. PubMed ID: 31788977
[TBL] [Abstract][Full Text] [Related]
4. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation.
Abdelhameed AS; Attwa MW; Kadi AA
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126762
[TBL] [Abstract][Full Text] [Related]
5. Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2020 Jan; 10(9):5412-5427. PubMed ID: 35498318
[TBL] [Abstract][Full Text] [Related]
6. LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling.
Attwa MW; Kadi AA; Darwish HW; Alrabiah H
Clin Chim Acta; 2018 Jul; 482():84-94. PubMed ID: 29614307
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation.
Attwa MW; Kadi AA; Alrabiah H; Darwish HW
J Pharm Biomed Anal; 2018 Oct; 160():19-30. PubMed ID: 30055343
[TBL] [Abstract][Full Text] [Related]
8. Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study.
Alsubi TA; Attwa MW; Darwish HW; Abuelizz HA; Kadi AA
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1435-1450. PubMed ID: 36738368
[TBL] [Abstract][Full Text] [Related]
9. Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Attwa MW; Kadi AA; Darwish HW
J Pharm Biomed Anal; 2019 Jul; 171():132-147. PubMed ID: 30999224
[TBL] [Abstract][Full Text] [Related]
10. Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation.
Attwa MW; Kadi AA; Abdelhameed AS
J Pharm Biomed Anal; 2019 Feb; 164():659-667. PubMed ID: 30472584
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of
Al-Shakliah NS; Attwa MW; AlRabiah H; Kadi AA
Anal Methods; 2021 Jan; 13(3):399-410. PubMed ID: 33410830
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites.
Abdelhameed AS; Attwa MW; Kadi AA
R Soc Open Sci; 2019 Aug; 6(8):190852. PubMed ID: 31598253
[TBL] [Abstract][Full Text] [Related]
13. Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS:
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Heliyon; 2023 Jun; 9(6):e17058. PubMed ID: 37484253
[TBL] [Abstract][Full Text] [Related]
14. Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC-MS/MS:
Kadi AA; Darwish HW; Abuelizz HA; Alsubi TA; Attwa MW
R Soc Open Sci; 2019 Jan; 6(1):181714. PubMed ID: 30800400
[TBL] [Abstract][Full Text] [Related]
15. Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Attwa MW; Kadi AA
RSC Adv; 2019 Oct; 9(57):32995-33006. PubMed ID: 35529145
[TBL] [Abstract][Full Text] [Related]
16. Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway.
Li AC; Yu E; Ring SC; Chovan JP
Rapid Commun Mass Spectrom; 2014 Jan; 28(1):123-34. PubMed ID: 24285397
[TBL] [Abstract][Full Text] [Related]
17. Metabolite characterization of ambrisentan, in in vitro and in vivo matrices by UHPLC/QTOF/MS/MS: Detection of glutathione conjugate of epoxide metabolite evidenced by in vitro GSH trapping assay.
Johnsi Rani P; Vishnuvardhan C; Nimbalkar RD; Garg P; Satheeshkumar N
J Pharm Biomed Anal; 2018 Jun; 155():320-328. PubMed ID: 29684813
[TBL] [Abstract][Full Text] [Related]
18. Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS:
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2018 Nov; 8(68):38733-38744. PubMed ID: 35558335
[TBL] [Abstract][Full Text] [Related]
19. LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.
Kadi AA; Attwa MW; Darwish HW
RSC Adv; 2018 Jan; 8(3):1182-1190. PubMed ID: 35540908
[TBL] [Abstract][Full Text] [Related]
20. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Argoti D; Liang L; Conteh A; Chen L; Bershas D; Yu CP; Vouros P; Yang E
Chem Res Toxicol; 2005 Oct; 18(10):1537-44. PubMed ID: 16533017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
